HC Wainwright Issues Optimistic Forecast for TYRA Earnings

Tyra Biosciences, Inc. (NASDAQ:TYRA) – Analysts at HC Wainwright raised their Q2 2026 earnings estimates for Tyra Biosciences in a research report issued on Tuesday, March 3rd. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($0.65) for the quarter, up from their previous estimate of ($0.66). HC Wainwright currently has a “Buy” rating and a $45.00 target price on the stock. The consensus estimate for Tyra Biosciences’ current full-year earnings is ($1.57) per share. HC Wainwright also issued estimates for Tyra Biosciences’ Q3 2026 earnings at ($0.67) EPS, Q4 2026 earnings at ($0.70) EPS and FY2026 earnings at ($2.66) EPS.

TYRA has been the subject of several other reports. Barclays initiated coverage on Tyra Biosciences in a report on Tuesday, January 27th. They issued an “overweight” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Wednesday, January 21st. Piper Sandler raised their price objective on shares of Tyra Biosciences from $33.00 to $42.00 and gave the stock an “overweight” rating in a research report on Friday, January 23rd. Cantor Fitzgerald started coverage on shares of Tyra Biosciences in a research note on Tuesday, February 24th. They issued an “overweight” rating for the company. Finally, Jefferies Financial Group lifted their price target on shares of Tyra Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a research report on Tuesday, February 3rd. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $42.33.

Tyra Biosciences Price Performance

TYRA stock opened at $34.54 on Thursday. Tyra Biosciences has a 1 year low of $6.42 and a 1 year high of $35.96. The firm has a market capitalization of $1.86 billion, a PE ratio of -17.18 and a beta of 1.06. The business has a 50 day simple moving average of $30.07 and a 200-day simple moving average of $20.96.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings data on Monday, March 2nd. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.03).

Insider Activity at Tyra Biosciences

In related news, Director Robert J. More sold 10,000 shares of the stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $25.00, for a total transaction of $250,000.00. Following the completion of the transaction, the director owned 3,823,425 shares of the company’s stock, valued at approximately $95,585,625. This trade represents a 0.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 15.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Dynamic Technology Lab Private Ltd acquired a new position in Tyra Biosciences during the 2nd quarter worth about $326,000. Sio Capital Management LLC grew its position in Tyra Biosciences by 94.5% in the 2nd quarter. Sio Capital Management LLC now owns 810,274 shares of the company’s stock valued at $7,754,000 after acquiring an additional 393,657 shares in the last quarter. Walleye Capital LLC increased its stake in Tyra Biosciences by 163.2% during the second quarter. Walleye Capital LLC now owns 370,408 shares of the company’s stock worth $3,545,000 after purchasing an additional 229,666 shares during the period. XTX Topco Ltd purchased a new stake in Tyra Biosciences during the second quarter worth about $331,000. Finally, Jump Financial LLC lifted its position in shares of Tyra Biosciences by 154.5% during the second quarter. Jump Financial LLC now owns 71,119 shares of the company’s stock worth $681,000 after purchasing an additional 43,170 shares in the last quarter. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.